<SEC-DOCUMENT>0001144204-17-062743.txt : 20171207
<SEC-HEADER>0001144204-17-062743.hdr.sgml : 20171207
<ACCEPTANCE-DATETIME>20171207130355
ACCESSION NUMBER:		0001144204-17-062743
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20171206
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171207
DATE AS OF CHANGE:		20171207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AntriaBio, Inc.
		CENTRAL INDEX KEY:			0001509261
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273440894
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54495
		FILM NUMBER:		171244302

	BUSINESS ADDRESS:	
		STREET 1:		1450 INFINITE DRIVE
		CITY:			LOUISVILLE
		STATE:			CO
		ZIP:			80027
		BUSINESS PHONE:		650-847-1919

	MAIL ADDRESS:	
		STREET 1:		1450 INFINITE DRIVE
		CITY:			LOUISVILLE
		STATE:			CO
		ZIP:			80027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FITS MY STYLE INC
		DATE OF NAME CHANGE:	20110104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv480957_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
December 6, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B><U>ANTRIABIO,
INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name of registrant in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Delaware</U></B></FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>000-54495</U></B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>27-3440894</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or jurisdiction</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">of incorporation or</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Identification No.)&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">organization)&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>1450 Infinite Drive</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Louisville, CO 80027</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>(303) 222-2128</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;(Registrant's telephone number)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;(Former name or former address, if
changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;&thinsp;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;&thinsp;240.12b-2 of this chapter). Emerging growth
company&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.01 Entry into a Material Definitive Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 6, 2017, AntriaBio, Inc. (the &ldquo;<B><U>Company</U></B>&rdquo;
or &ldquo;<B><U>we</U></B>&rdquo;) entered into a License Agreement (&ldquo;<B><U>License Agreement </U></B>&ldquo;) with XOMA
LLC (&ldquo;<B><U>XOMA</U></B>&rdquo;) pursuant to which the Company acquired the exclusive rights to develop and commercialize
XOMA 358 (now RZ358) for an orphan indication, Congenital Hyperinsulinism. The Company and XOMA also entered into a Common Stock
Purchase Agreement (&ldquo;<B><U>Purchase Agreement</U></B>&rdquo;) in connection with the License Agreement (collectively, the
License Agreement and the Purchase Agreement may be hereinafter referred to as the (&ldquo;<B><U>Transaction Documents</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the License Agreement, the Company is responsible
for all development, regulatory, manufacturing and commercialization activities associated with RZ358. Pursuant to the Transaction
Documents, the Company is required to pay XOMA $6 million and to issue XOMA $12 million of the Company&rsquo;s common stock based
upon the Company&rsquo;s financing activities in 2018. Under the License Agreement, the Company is also required to make certain
clinical, regulatory and annual net sales milestone payments of up to $222 million in the aggregate. The Company is also obliged
to pay XOMA royalties ranging from the high single digits to the mid-teens based upon annual net sales of RZ358. Finally, under
the terms of the License Agreement, the Company is required to pay XOMA a low single digit royalty on sales of the Company&rsquo;s
other products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3.02 Unregistered Sales of Equity Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information disclosed in Item 1.01
of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. The issuance of the Shares have been determined
to be exempt from registration under the Act in reliance on Section 4(a)(2) thereof as a transaction by an issuer not involving
a public offering, in which the investor is accredited and has acquired the securities for investment purposes only and not with
a view to or for sale in connection with any distribution thereof. Such securities may not be offered or sold in the United States
absent registration or an applicable exemption from registration requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 5.03.&nbsp;Amendments to Articles of Incorporation
or Bylaws; Changes in Fiscal Year.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 7, 2017, the Company filed a Certificate of Ownership
and Merger with the Secretary of State of Delaware to effectuate a merger whereby the Company would merge with its wholly-owned
subsidiary, Rezolute, Inc., through a parent/subsidiary merger, with the Company as the surviving corporation. This merger, which
will become effective on December 18, 2017 (the &ldquo;<B><U>Effective Time</U></B>&rdquo;), as pursuant to Section
253 of the General Corporation Law of Delaware. Shareholder approval for this merger was not required under Section 253 of the
General Corporation Law of Delaware. Upon the Effective Time of this merger, the Company&rsquo;s name will change to &ldquo;Rezolute,
Inc.&rdquo; and the Registrant's Articles of Incorporation will be amended to reflect this name change. In connection with the
name change, the company anticipates that its CUSIP number and trading symbol will be changed. Upon issuance of its new CUSIP number
and trading symbol, the company will file an additional Current Report on Form 8-K. The Company has also filed an issuer company
relation action notification with the Financial Industry Regulatory Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the Articles of Merger and Agreement and Plan of Merger
as filed herewith as Exhibit 2.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.01. Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 7, 2017, we issued the press release attached hereto
as Exhibit 99.1 and a shareholder letter attached hereto as Exhibit 99.2.&nbsp;&nbsp;In accordance with General Instruction B.2
of Form 8-K, the information set forth herein and in the press release is deemed to be &ldquo;furnished&rdquo; and shall not be
deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended.&nbsp;&nbsp;The information set
forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information
in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-top: 0; padding-right: 0; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>EXHIBIT</B></FONT></TD>
    <TD STYLE="width: 2%; padding: 0 0 1pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 88%; padding-top: 0; padding-right: 0; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>DESCRIPTION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv480957_ex2-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">2.1</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv480957_ex2-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certificate of Ownership and Merger</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv480957_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv480957_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press Release of Antriabio, Inc. dated December 6, 2017*</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv480957_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.2</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv480957_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Shareholder Letter of AntriaBio, Inc. dated December 6, 2017*</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* The following exhibit relating to Item 7.01 is intended to
be furnished to, not filed with, the SEC pursuant to Regulation FD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ANTRIABIO, INC.</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">DATE:&nbsp;&nbsp;December 7, 2017</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Nevan Elam</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nevan Elam</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer &amp; Chairman of the Board</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-top: 0; padding-right: 0; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>EXHIBIT</B></FONT></TD>
    <TD STYLE="width: 2%; padding: 0 0 1pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 88%; padding-top: 0; padding-right: 0; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>DESCRIPTION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv480957_ex2-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">2.1</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv480957_ex2-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certificate of Ownership and Merger</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv480957_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv480957_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press Release of Antriabio, Inc. dated December 6, 2017*</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv480957_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.2</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv480957_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Shareholder Letter of AntriaBio, Inc. dated December 6, 2017*</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* The following exhibit relating to Item 7.01 is intended to
be furnished to, not filed with, the SEC pursuant to Regulation FD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>tv480957_ex2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 2.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATE OF OWNERSHIP AND MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>MERGING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REZOLUTE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(a Delaware corporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INTO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ANTRIABIO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(a Delaware corporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">AntriaBio, Inc., a Delaware corporation
(the &ldquo;Company&rdquo;), in accordance with Section 253 of the Delaware General Corporation Law, does hereby certify as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is incorporated pursuant to the laws of the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company owns all of the outstanding shares of common stock of Rezolute, Inc., a Delaware corporation (the &ldquo;Subsidiary&rdquo;).
The Subsidiary has no shares of any other class or series of stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company, by the following resolutions of its Board of Directors, duly adopted on December 2, 2017, determined to merge into itself
the Subsidiary on the conditions set forth in such resolutions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><B>WHEREAS</B>, this Board of Directors
desires to approve the merger of Rezolute, Inc., a wholly-owned Delaware subsidiary of the Company (the &ldquo;Subsidiary&rdquo;),
with and into the Company and establish the terms and conditions of such merger in accordance with the provisions of Section 253
of the Delaware General Corporation Law;<BR>
&nbsp;<BR>
<B>NOW BE IT, RESOLVED</B>, that the merger of the Subsidiary with and into the Company pursuant to the provisions of Section 253
of the Delaware General Corporation Law and the provisions set forth below is hereby approved.<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><B>RESOLVED</B>, that, on the date
that is ten (10) calendar days from the date a Certificate of Ownership and Merger is filed with the Delaware Secretary of State
(the &ldquo;Effective Date&rdquo;), the identity, existence, purposes, powers, objects, franchises, privileges, rights and immunities
of the Company shall continue in effect and unimpaired by the merger, and the corporate franchises, existence and rights of the
Subsidiary shall be merged into the Company and the Company shall, as the surviving corporation, be fully vested therewith; and,
further, that the separate existence and corporate organization of the subsidiary, except as they may continue by statute, shall
cease of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><B>RESOLVED</B>, that, as of the
Effective Date, all shares of the Subsidiary&rsquo;s Common Stock held by the Company shall be cancelled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><B>RESOLVED</B>, that the Certificate
of Incorporation of the Company shall continue to be the Certificate of Incorporation of the Company as the surviving corporation
and shall remain in effect until it shall be amended or altered in accordance with the provisions thereof; provided, however, that
Article I of such Certificate of Incorporation shall be amended to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;FIRST: The Name of the
Corporation is Rezolute, Inc.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><B>RESOLVED</B>, that the officers
of the Company are hereby authorized and directed to execute a Certificate of Ownership and Merger in accordance with the terms
set forth in these resolutions and to file, or tender for filing, and record and take such other action as may be necessary to
effectuate the merger and the actions contemplated hereby in any and all jurisdictions where such filing, recording or other action
shall be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Certificate of Ownership and Merger shall be effective on December 18, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the undersigned
has signed his name and affirmed that this instrument is the act and deed of the Company and that the statements herein are true,
under penalties of perjury, this 6<SUP>th</SUP> day of December, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[The remainder of this page is intentionally
left blank.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>ANTRIABIO, INC.,</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">a Delaware corporation</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">By:</TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid">/s/ Nevan Elam</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">Name:&nbsp;&nbsp;Nevan Elam</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">Title:&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tv480957_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B><IMG SRC="image_001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AntriaBio Announces Exclusive License
Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LOUISVILLE, Colorado, December 7, 2017 &ndash; (GLOBE NEWSWIRE)
&ndash; <U>Rezolute, Inc.</U> (&ldquo;Rezolute&rdquo; or the &ldquo;Company&rdquo;) (OTCQB: ANTB), </B>a <FONT STYLE="background-color: white">clinical
stage biopharmaceutical company specializing in the development of innovative drug therapies for metabolic and orphan diseases,
and </FONT><B><U>XOMA Corporation</U> (&ldquo;XOMA&rdquo;) (NASDAQ: XOMA)</B>, a pioneer in the discovery, development and licensing
of therapeutic antibodies, <FONT STYLE="background-color: white">announced today </FONT>that they have executed a license agreement
that provides Rezolute with the exclusive global rights to develop and commercialize <U>RZ358</U> (formerly <U>XOMA 358</U>) for
Congenital Hyperinsulinism (CHI), an ultra-orphan indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RZ358 is a first-in-class fully human monoclonal antibody that
counteracts the effects of elevated insulin via allosteric modulation of the insulin receptor, making it well-suited as a therapy
for severe, persistent hypoglycemia caused by hyperinsulinemic conditions such as CHI. XOMA demonstrated clinical proof-of-concept
through Phase 2a studies and Rezolute plans to advance clinical development in 2018. The compound has received designated orphan
status in the US and European Union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are excited about the addition of RZ358 to our growing
product pipeline and for the opportunity to take a Phase 2 program forward with the hope of being able to offer a significantly
better treatment option for a disease that is the most frequent cause of severe, persistent hypoglycemia in newborn babies and
children,&rdquo; said Nevan Elam, Chairman and Chief Executive Officer of Rezolute. &ldquo;XOMA has generated compelling safety
data and proof-of-concept for RZ358 and we look forward to advancing its development.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the agreement, Rezolute will assume the
global development, regulatory filings, manufacturing and commercialization for RZ358. In turn, XOMA will receive a total of $18
million in the form of cash and shares of Rezolute common stock and will be eligible to receive up to an aggregate of $222 million
in clinical, regulatory and sales milestones. In addition, XOMA is entitled to receive royalties ranging from the high single
digits to the mid-teens based upon annual net sales of RZ358. Finally, under the terms of the agreement, Rezolute will pay XOMA
low single digit royalties on sales of the company&rsquo;s other products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Having established proof-of-concept for XOMA 358 earlier
this year, we look forward to Rezolute continuing clinical development of the program,&rdquo; stated Jim Neal, Chief Executive
Officer of XOMA. &ldquo;Our license agreement with Rezolute places this important drug asset in the hands of a very capable endocrine-focused
team, provides XOMA with the potential to receive future milestones and royalties, and is an important milestone in the continued
transformation of our programs to fully-funded status. We welcome Rezolute to our broad portfolio of partners, including Novartis,
Five Prime and NanoTherapeutics, who continue the development of our product candidates.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CHI is a rare genetic disorder that affects one in 50,000 newborns.
Ordinarily, beta cells in the pancreas secrete just enough insulin to keep blood sugar in the normal range. With CHI, the secretion
of insulin is not properly regulated as the beta cells secrete too much insulin resulting in excessive low blood sugar (severe
hypoglycemia). In infants and young children, these episodes are characterized by lethargy, irritability and difficulty feeding.
Repeated episodes of hypoglycemia increase the risk of serious complications such as breathing difficulties, seizures, developmental
delays and intellectual disability, vision loss, brain damage, coma and possibly death. CHI is the most common cause of persistent
hypoglycemia in children and about 60 percent of infants with CHI experience a hypoglycemic episode within the first month of life.
Other affected children develop hypoglycemia by early childhood. A significant number of patients cannot be adequately treated
with or do not tolerate existing medical therapies. Surgical removal of all or part of the pancreas is a cornerstone of management
for many patients, but is invasive and diabetes-inducing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s new name reflects its transition as a developer
of potentially paradigm-shifting therapies for treating metabolic diseases and orphan indications with high unmet medical needs.
Under this strategy, the Company also exclusively licensed <U>ActiveSite Pharmaceuticals</U>&rsquo; oral plasma kallikrein inhibitor
(PKI) portfolio in August and is developing <U>RZ402</U> for Diabetic Macular Edema and <U>RZ602</U> for Hereditary Angioedema,
an orphan indication.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;The name change conveys our dedication to
identifying and developing therapies that are transformative and target well-known genetic pathways and mechanisms,&rdquo;
stated Mr. Elam. With the recent licensing agreements executed with XOMA Corporation for a monoclonal antibody to treat CHI,
an orphan indication, and <U>ActiveSite Pharmaceuticals</U> for our oral Plasma Kallikrein Inhibitor (PKI) portfolio, we have
evolved into a company advancing a robust pipeline of innovative solutions for patients and providers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Rezolute, Inc.</B><BR>
Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve
the lives of patients with metabolic and orphan diseases. Rezolute is advancing a diversified pipeline including: RZ358 (Phase
2), an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy; AB101
(Phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management
by reducing the therapeutic burden for patients and improving compliance; and a Plasma Kallikrein Inhibitor (PKI) portfolio with
two lead compounds, RZ402 (plan to file IND in H2 2018) targeting Diabetic Macular Edema (DME) and RZ602 (plan to file IND in
H1 2019) targeting Hereditary Angioedema (HAE), an orphan indication. For more information, visit: <U>www.rezolutebio.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About XOMA Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">XOMA has an extensive portfolio of products, programs, and
technologies that are the subject of licenses the Company has in place with other biotech and pharmaceutical companies. Many of
these licenses are the result of the Company's pioneering efforts in the discovery and development of antibody therapeutics. There
are more than two dozen such programs that are fully funded by partners and could produce milestone payments and royalty payments
in the future. For more information, visit <U>www.xoma.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B><BR>
This release, like many written and oral communications presented by Rezolute, Inc. and our authorized officers, may contain certain
forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements
to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform
Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are
based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by
use of words such as &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;intend,&quot;
&quot;plan,&quot; &quot;project,&quot; &quot;seek,&quot; &quot;strive,&quot; &quot;try,&quot; or future or conditional verbs such
as &quot;could,&quot; &quot;may,&quot; &quot;should,&quot; &quot;will,&quot; &quot;would,&quot; or similar expressions. Our ability
to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ
materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation
to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements
were made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B><IMG SRC="image_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Rezolute, Inc. Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Noopur Liffick</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">VP of Corporate Development</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(650) 549-4175</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">investor-relations@rezolutebio.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Source: Rezolute, Inc.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>tv480957_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">A Letter From The Chairman &amp; CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Colleagues, Shareholders and Friends:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Today we issued a <U>press release</U>
announcing our agreement with XOMA Corporation to in-license RZ358, a Phase 2 antibody to treat Congenital Hyperinsulinism (CHI),
an ultra-orphan metabolic disease. With the addition of this program to our product pipeline, we have achieved a significant milestone
in our corporate evolution, and the purpose of this letter is to update you on our go-forward plans as well as the status of the
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In my 2016 letter to shareholders, I highlighted
our belief in the importance of advancing our microsphere platform while opportunistically seeking to in-license or acquire external
programs and capabilities that could facilitate the creation of a robust, high-value biopharmaceutical company. Our corporate development
activities this year reflect the implementation of that strategy. We believe the best way to increase shareholder value and unlock
the possibility of up-listing onto a national stock exchange with the support of institutional investors is to advance multiple
pipeline programs at different stages across different platforms. I am happy to inform you that we now have four active programs
across three platforms including: (i) a Phase 2 antibody (RZ358), (ii) a Phase 1 microsphere (AB101), and (iii) two preclinical
oral plasma kallikrein inhibitors (RZ402 and RZ602).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In just a few months we have transformed
the company from a microsphere-based diabetes organization to a clinical stage metabolic and orphan disease company with a portfolio
of potentially paradigm-shifting therapies for patients and providers. &ldquo;AntriaBio&rdquo; is and will remain known as the
microsphere company developing a long-acting insulin. With the broadening of our capabilities, programs and mission, we are emphasizing
our new mandate. By changing the company&rsquo;s name to &ldquo;Rezolute,&rdquo; we are resolved to apply different technologies
and modalities to develop transformative therapies for diseases with high unmet needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RZ358</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">CHI is a rare
genetic disorder that affects 1 in 50,000 newborns. Ordinarily, beta cells in the pancreas secrete just enough insulin to keep
blood sugar in the normal range. With CHI, the secretion of insulin is not properly regulated as the beta cells secrete too much
insulin resulting in excessive low blood sugar (severe hypoglycemia). In infants and young children, these episodes are characterized
by lethargy, irritability and difficulty feeding. Repeated episodes of hypoglycemia increase the risk of serious complications
such as breathing difficulties, seizures, developmental delays and intellectual disability, vision loss, brain damage, coma and
possibly death. CHI is the most common cause of persistent hypoglycemia in children and about 60 percent of infants with CHI experience
a hypoglycemic episode within the first month of life. Other affected children develop hypoglycemia by early childhood.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To avoid hypoglycemia, many children require
frequent glucose monitoring and feeding, including intravenous or intestinal administration of sugar solutions, particularly overnight.
This burdensome treatment regimen has a substantially negative effect on the quality of life for these children and their families.
In addition, a significant number of children cannot be adequately treated with, or do not tolerate, existing medical therapies.
Surgical removal of all or part of the pancreas is a cornerstone of management for many children, but is invasive and diabetes-inducing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border-top: gray 2.25pt solid; border-right: gray 2.25pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 90%; border-top: gray 2.25pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #033259">1450 Infinite Drive, Louisville, CO 80027</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #033259">P: 303.222.2128</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #033259">www.rezolutebio.com</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RZ358 is a first-in-class fully human monoclonal
antibody that counteracts the effects of elevated insulin (hyperinsulinemia) by, in effect, turning down the insulin receptor when
too much insulin is present, making it well-suited as a treatment for severe, persistent hypoglycemia. XOMA demonstrated clinical
proof-of-concept for RZ358 in Phase 2a studies and the compound has designated orphan status in the US and EU. We are preparing
to launch Phase 2b studies in 2018 with the potential to accelerate late-stage pivotal trials for an abbreviated path-to-market
strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>AB101</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a prerequisite to engaging in our corporate
development/in-licensing activities, we first wanted to realize the objective that was the basis for the formation of AntriaBio.
The primary reason most of us invested our time, energy and money was to advance AB101, a once-weekly injectable basal insulin
for patients with diabetes, into the clinic as a potential disruptive therapy in the $11 billion basal insulin market that is still
dominated by insulin analogs administered by daily injections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A year ago, we set a corporate goal to
complete a successful manufacturing campaign, file an investigational new drug application (IND) with the US Food &amp; Drug Application
(FDA) and start our Phase 1 first-in-human clinical study of AB101, all by the middle of 2017. In fact, we achieved each of these
objectives: we produced sterile AB101 material in the first half of 2017; we filed our IND in June; and we recently completed the
first of up to five potential cohorts in the AB101 clinical study being conducted at ProSciento, a contract research organization
in Southern California. We look forward to dosing the next cohort in the new year, with the goal of demonstrating that the pharmacological
profile of AB101 lasts for more than a week while meaningfully lowering glucose levels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PKI Portfolio</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August of this year, soon after initiating
our first-in-human study of AB101, we took the first step in realizing our corporate development objectives by in-licensing ActiveSite
Pharmaceuticals&rsquo; oral plasma kallikrein inhibitor (PKI) portfolio. In our evaluation of the PKI portfolio, we became increasingly
convinced of its potential to address serious diseases. Further, we believe the PKI portfolio may be the most advanced oral program
in the space, given the extensive preclinical work previously conducted, including not only <I>in vitro</I> modeling, but also
<I>in vivo</I> studies in the rodent, dog and monkey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Plasma kallikrein is an enzyme that is
part of the kinin system, which is a complex metabolic cascade that can play a prominent role in inflammation. Specifically, plasma
kallikrein ultimately contributes to the production of a peptide called bradykinin, which causes blood vessels to enlarge or dilate,
resulting in problematic inflammation and vascular leakage. By inhibiting the formation of plasma kallikrein and the subsequent
production of bradykinin, we believe we may be able to treat metabolic and orphan diseases associated with vascular leakage. For
example, diabetic macular edema (DME) and hereditary angioedema (HAE) are two diseases that are impacted by the kinin system that
could potentially benefit from an oral PKI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RZ402</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DME is a metabolic disease that results
from an increase in retinal vascular permeability (RVP) in the setting of diabetic retinopathy (abnormal retinal blood vessel growth
caused by poorly controlled blood sugar levels). Vascular leakage from retinal blood vessels leads to swelling of the retina, including
the macula, an area of the retina that is very important for vision. The kinin system and the production of bradykinin have been
implicated in the vascular leakage associated with DME. It is estimated that approximately 50 million individuals worldwide suffer
from vision-threatening complications of diabetes, including DME, which is one of the main causes of vision loss in working-age
adults globally. With the growth of diabetes, DME is expected to increase in prevalence beyond its current estimate of 750,000
individuals in the US and 21 million worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Current treatment approaches are onerous,
involving injections into the eye by retinal specialists on a monthly or bimonthly basis. In addition to a segment of the DME population
that does not respond to these treatments, the extent of therapeutic benefit directly correlates with adherence to this route of
administration and regimen, which is a significant burden for both patients and their healthcare providers, leading to high rates
of non-adherence and ultimately, suboptimal therapeutic outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RZ402 is a potential new therapy for DME
from the PKI portfolio. RZ402 has been shown to normalize RVP in clinically-relevant animal models of macular edema as effectively
as the current injectable treatments, thereby supporting its potential as a stand-alone therapy for macular edema resulting from
diabetes and other causes. We are planning to file an IND for RZ402 in the second half of 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RZ602</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">HAE is <FONT STYLE="background-color: white">an
orphan disease </FONT>characterized by recurring attacks of sudden and extreme swelling that can affect the face and mucous membranes,
abdomen and genitalia. Attacks can be painful, debilitating, varied in frequency and even life-threatening, due to <FONT STYLE="background-color: white">swelling
around the airway. The disease is caused by a problem with a gene that controls the management of a specific protein, the C1 inhibitor.
When there is an imbalance in the C1 inhibitor, there may be excessive bradykinin production causing tiny blood vessels to &ldquo;leak&rdquo;
or push fluid into parts of the patient&rsquo;s body, resulting in an HAE attack. The trigger for an attack is variable from person
to person and even time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently available therapies target the
prevention or termination of attacks, but are highly invasive and inconvenient due to the subcutaneous/intravenous routes of administration
or have an undesirable side effect profile. Approximately one in 50,000 patients worldwide have HAE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RZ602 is a potential new therapy for HAE
from the PKI portfolio. Similar to our efforts with RZ402 for DME, the objective of RZ602 is to stop the inflammatory cascade by
inhibiting the production of kallikrein and thereby halting the downstream release of bradykinin and eventual swelling. We plan
to file an IND for RZ602 in the first half of 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notably, in October of this year, one of
our competitors, KalVista, announced a transaction with Merck whereby Merck agreed to pay KalVista $37 million up front and up
to $715 million in milestone payments for an intravitreal (injection into the eye) PKI currently in Phase 2, as well as other potential
preclinical oral PKIs for DME. Merck also agreed to take a 10% equity stake in KalVista with a $9 million investment. We believe
this transaction validates the potential utility of the kallikrein pathway in treating certain diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Pipeline Activities </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research scientists are actively leveraging
our multiple platform technologies to formulate new compounds, conduct studies and screen potential new product candidates as we
seek to evolve our product pipeline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Expansion of our Board of Directors
and Scientific Advisory Board</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparation for a potential up-listing
to a national exchange in 2018, this year we added several new members to our Board of Directors (Board) and implemented certain
governance requirements, including the creation of various Board committees. In October, we announced our newest Board member,
Gil Labrucherie, who is Chief Financial Officer of Nektar Therapeutics, a biopharmaceutical company. In March, two other pharmaceutical
executives joined the Board, including Tae Hoon Kim and Samir R. Patel, M.D. Mr. Kim is currently Chief Executive Officer of Aju
Pharm, a pharmaceutical company in the Republic of Korea and Dr. Patel is co-founder, principal and former CEO of SPEC Pharma,
LLC. Finally, in October Dr. Robert Bhisitkul joined our Scientific Advisory Board and he is a retinal specialist and Professor
of Clinical Ophthalmology at the University of California, San Francisco School of Medicine. His expertise in DME drug development
will be invaluable as we advance RZ402 into the clinic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Capital Requirements and Effect of Name
Change</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given our current financial needs as well
as our desired strategy to advance our product pipeline candidates, we are planning to raise capital in the first half of 2018,
primarily from institutional investors. We anticipate our capital-raising activities may include the issuance of equity or debt
securities, obtaining credit facilities or other financing mechanisms. Clearly, if we are unable to raise capital, our prospects
will be materially and adversely impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s name change does not
affect our corporate structure. The rights of stockholders holding certificated shares under currently outstanding stock certificates
and the number of shares represented by those certificates will remain unchanged. The name change does not affect the validity
or transferability of any currently outstanding stock certificates nor will it be necessary for stockholders with certificated
shares to surrender any stock certificates they currently hold as a result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Closing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hope you share in our excitement about
today&rsquo;s announcement regarding RZ358 and our evolution as a company. With the addition of RZ358 as well as RZ402 and RZ602,
we have &ldquo;more shots on goal&rdquo; with a diversification strategy centered around metabolic and orphan diseases. We are
not dependent upon any single pipeline candidate for success. Through our corporate development activities, we have significantly
increased the value and attractiveness of the company. I am particularly pleased we have been able to accomplish the in-licensing
of RZ358 and the PKI portfolio with only $750,000 in upfront cash and minimal dilution. This is a phenomenal achievement and virtually
unprecedented in our industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2018, we have the following five primary
goals:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">raise capital and up-list onto a national exchange;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">prepare for and initiate a Phase 2b study of RZ358;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">complete our ongoing Phase 1 study of AB101;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">complete the requisite preclinical work and file an IND for RZ402; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(5)</TD><TD STYLE="text-align: justify">name one project currently in discovery as a pipeline candidate based upon <I>in vivo</I> studies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I encourage you to visit our revised website
and review our new <U>corporate presentation</U> with more information about our programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In closing, I would like to thank all of
our stakeholders, particularly our investors, for their patience and taking a long-term view of our potential as a high-value biopharmaceutical
company. We believe the steps we have taken this year to evolve the company have significantly contributed to shareholder value.
We are resolved to push forward in 2018 &ndash; we are <I>Rezolute</I>!</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With warm regards,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 44.25pt; width: 136.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nevan C. Elam</B><BR>
Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This shareholder letter, like many written and oral communications
presented by AntriaBio, Inc. and Rezolute, Inc. (the &ldquo;Company&rdquo;), and our authorized officers, may contain certain forward-looking
statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be
covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act
of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based
on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use
of words &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;plan,&quot;
&quot;project,&quot; &quot;seek,&quot; &quot;strive,&quot; &quot;try,&quot; or future or conditional verbs such as &quot;could,&quot;
&quot;may,&quot; &quot;should,&quot; &quot;will,&quot; &quot;would,&quot; or similar expressions. Our ability to predict results
or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from
anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as
of the date of this letter. Except as required by applicable law or regulation, the Company undertakes no obligation to update
these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' 8 # 2(  A$! Q$!_\0
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MQ.!GH,\^E="P[<>9LYW77-RI'L'Q)^(L/@ZS%G9A)M8N%S&C<K"O]]OZ#O\
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M$U73';(MIUE0$] X(/ZI^M>O5A.'))Q-X2YXJ1Y>WQV\,JS*;'5<@D?ZI/\
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MQ?\ 7_%_Z"].^!W_ "3]O^OV7^2UI_RX^9E_R_\ D>E5YE\=/^1"@_Z_XO\
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M*R?QS^7@2^^' P/3/K5"T63PE;7WA#5X/*N]4U""*>7&1% I^66,]R6;(/\
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M@LD0^6)"1P2J*H^N:WJ3;7NIZ#2OK;4*S-<\/Z7XDL%L=7M1<VRR"0(79?F
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CRA@WE1C[JY'&3R3CV]***4JTY1Y65&C",N9'HM%%%8FI_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "= >0# 2(  A$! Q$!_\0
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MC'KWK:CAJE6[BM!.26YZ?134.44^U.K H**** "BBB@ HHHH **** "BBB@
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M110 4444 %%&:,T %%%% !1110 4444 %%%% !1110 4444 %%%% !11FDW
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MV:;+6VAA7&,1H%'Z58HK.4YR^)MCL&/PHQ2T5(!1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
